R Daniel Rudic1, Derek Brinster, Yan Cheng
1The Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia 19104, USA.
Selective COX-2 inhibitors reduce prostacyclin (PGI2), increasing vascular hyperplasia and reducing blood flow. This suggests a link between COX-2 inhibition and cardiovascular risk during prolonged use.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: